Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 8/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | CNR2 | P34972 | 1/20 | 0.45 |
| ▸ | DPP4 | P27487 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14413341 | 0.86 | EPHX2 (0.41) | EPHX2MEN1KMT2AALDH1A1LMNA | |
| SCHEMBL13873338 | 0.81 | ALDH1A1 (0.57) | EPHX2KMT2AALDH1A1HTT | |
| SCHEMBL4106627 | 0.80 | EPHX2 (0.57) | EPHX2MEN1KMT2AALDH1A1LMNA | |
| SCHEMBL4100281 | 0.78 | EPHX2 (0.72) | EPHX2MEN1KMT2AALDH1A1LMNA | |
| SCHEMBL4099352 | 0.77 | EPHX2 (0.70) | EPHX2MEN1KMT2AALDH1A1LMNA | |
| SCHEMBL7823189 | 0.75 | CCR3 (0.57) | EPHX2EPHX1CNR2 | |
| SCHEMBL14412844 | 0.74 | EPHX2 (0.57) | EPHX2MEN1KMT2AALDH1A1 | |
| SCHEMBL3056025 | 0.72 | EPHX2 (0.47) | EPHX2MEN1KMT2AALDH1A1LMNA | |
| SCHEMBL27924792 | 0.71 | LIPE (0.52) | EPHX2MEN1KMT2AALDH1A1HTT | |
| SCHEMBL13873361 | 0.71 | HSD11B1 (0.47) | EPHX2ALDH1A1EPHX1DPP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090111791-A1 | Soluble Epoxide Hydrolase Inhibitors and Methods of Using Same | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-04-30 | — | — | US | disclosed |
| US-20090111791-A1 | Soluble Epoxide Hydrolase Inhibitors and Methods of Using Same | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-04-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090111791-A1 | Soluble Epoxide Hydrolase Inhibitors and Methods of Using Same | EPHX1, EPHX2, NCEH1 | EPHX2 2/4885MEN1 4174/4885KMT2A 3145/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.